Liquidia Corporation Q3 2026 Earnings Recap

Liquidia’s shares rose 7.4% after earnings, as investors appeared to reward 31% third-quarter net product sales growth and signs that YUTREPIA shipments reached a launch high in October despite litigation-related uncertainty. The outlook remains dependent on referrals recovering from October’s pause; management described October as a floor, but that recovery has yet to be demonstrated.

Key Takeaways

• Third-quarter net product sales grew 31% to $222.7 million; management said YUTREPIA had recorded five consecutive quarters of growth in prescriptions, revenue and adjusted EBITDA.
• In October, the first full month after the ruling, monthly shipments to patients reached their highest level since launch. Daily referrals were more than 75% of the Q3 rate, while conversion rates remained above 87%.
• PAH accounted for more than 60% of prescriptions from launch through September and over 70% in September. Liquidia reported approximately 1,300 prescribers; 60% had written for at least two patients.
• Litigation-related uncertainty weighed on referrals at some centers. Management expects referrals to recover, but that expectation is not yet established by October’s referral rate.
• The pipeline adds longer-term milestones: RE-WARM enrollment is expected to complete in the first half of 2027; L606’s pivotal PH-ILD study is expected to complete enrollment in 2028, with data from its pivotal studies intended to support an NDA submission in 2029.